{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:55:23Z","timestamp":1790668523548,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-026-01288-x","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T17:51:05Z","timestamp":1788976265000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring a Persistent Terbinafine \u2013 CYP2D6 Interaction Using Physiologically \u2013 Based Pharmacokinetic Modeling"],"prefix":"10.1208","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0709-9528","authenticated-orcid":false,"given":"Devendra","family":"Pade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9434-1302","authenticated-orcid":false,"given":"Jan","family":"Wahlstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"issue":"sup 2","key":"1288_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3109\/09546639009089024","volume":"1","author":"J Jensen","year":"1990","unstructured":"Jensen J. Pharmacokinetics of Lamisil\u00ae in humans. J Dermatolog Treat. 1990;1(sup 2):15\u20138.","journal-title":"J Dermatolog Treat"},{"key":"1288_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/BF03258479","volume":"8","author":"H Zehender","year":"1994","unstructured":"Zehender H, Cabiac MD, Denou\u00ebl J, Faergemann J, Donatsch P, Kutz K, Humbert H. Elimination kinetics of terbinafine from human plasma and tissues following multiple-dose administration, and comparison with 3 main metabolites. Drug Invest. 1994;8:7.","journal-title":"Drug Invest"},{"issue":"8","key":"1288_CR3","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/bdd.2510160807","volume":"16","author":"H Humbert","year":"1995","unstructured":"Humbert H, Cabiac MD, Denou\u00ebl J, Kirkesseli S. Pharmacokinetics of terbinafine and of its five main metabolites in plasma and urine, following a single oral dose in healthy subjects. Biopharm Drug Dispos. 1995;16(8):685\u201394.","journal-title":"Biopharm Drug Dispos"},{"issue":"9","key":"1288_CR4","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S0090-9556(24)15022-2","volume":"27","author":"AE Vickers","year":"1999","unstructured":"Vickers AE, Sinclair JR, Zollinger M, Heitz F, Gl\u00e4nzel U, Johanson L, et al. Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. Drug Metab Dispos. 1999;27(9):1029\u201338.","journal-title":"Drug Metab Dispos"},{"key":"1288_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2019.113661","volume":"170","author":"DA Barnette","year":"2019","unstructured":"Barnette DA, Davis MA, Flynn N, Pidugu AS, Swamidass SJ, Miller GP. Comprehensive kinetic and modeling analyses revealed CYP2C9 and 3A4 determine terbinafine metabolic clearance and bioactivation. Biochem Pharmacol. 2019;170.","journal-title":"Biochem Pharmacol"},{"issue":"11","key":"1288_CR6","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1177\/009127002762491299","volume":"42","author":"S Madani","year":"2002","unstructured":"Madani S, Barilla D, Cramer J, Wang Y, Paul C. Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers. J Clin Pharmacol. 2002;42(11):1211\u20138.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"1288_CR7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1128\/AAC.02006-13","volume":"58","author":"MJ Dolton","year":"2014","unstructured":"Dolton MJ, Perera V, Pont LG, McLachlan AJ. Terbinafine in combination with other antifungal agents for treatment of resistant or refractory mycoses: investigating optimal dosing regimens using a physiologically based pharmacokinetic model. Antimicrob Agents Chemother. 2014;58(1):48\u201354.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"1288_CR8","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1128\/AAC.46.7.2219-2228.2002","volume":"46","author":"M Hosseini-Yeganeh","year":"2002","unstructured":"Hosseini-Yeganeh M, McLachlan AJ. Physiologically based pharmacokinetic model for terbinafine in rats and humans. Antimicrob Agents Chemother. 2002;46(7):2219\u201328.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 39","key":"1288_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1365-2133.1992.tb00002.x","volume":"126","author":"JM Kovarik","year":"1992","unstructured":"Kovarik JM, Kirkesseli S, Humbert H, Grass P, Kutz K. Dose-proportional pharmacokinetics of terbinafine and its N-demethylated metabolite in healthy volunteers. Br J Dermatol. 1992;126(Suppl 39):8\u201313.","journal-title":"Br J Dermatol"},{"issue":"12","key":"1288_CR10","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1128\/AAC.39.12.2738","volume":"39","author":"JM Kovarik","year":"1995","unstructured":"Kovarik JM, Mueller EA, Zehender H, Denou\u00ebl J, Caplain H, Millerioux L. Multiple-dose pharmacokinetics and distribution in tissue of terbinafine and metabolites. Antimicrob Agents Chemother. 1995;39(12):2738\u201341.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3\u20134","key":"1288_CR11","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/j.1439-0507.1995.tb00037.x","volume":"38","author":"T Matsumoto","year":"1995","unstructured":"Matsumoto T, Tanuma H, Kaneko S, Takasu H, Nishiyama S. Clinical and pharmacokinetic investigations of oral terbinafine in patients with tinea unguium. Mycoses. 1995;38(3\u20134):135\u201344.","journal-title":"Mycoses"},{"issue":"5","key":"1288_CR12","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1097\/01.ftd.0000175910.68539.33","volume":"27","author":"I Castberg","year":"2005","unstructured":"Castberg I, Helle J, Aamo TO. Prolonged pharmacokinetic drug interaction between terbinafine and amitriptyline. Ther Drug Monit. 2005;27(5):680\u20132.","journal-title":"Ther Drug Monit"},{"issue":"7129","key":"1288_CR13","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1136\/bmj.316.7129.441","volume":"316","author":"PH van der Kuy","year":"1998","unstructured":"van der Kuy PH, Hooymans PM. Nortriptyline intoxication induced by terbinafine. BMJ. 1998;316(7129):441.","journal-title":"BMJ"},{"issue":"2","key":"1288_CR14","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1208\/s12248-009-9099-y","volume":"11","author":"M Jamei","year":"2009","unstructured":"Jamei M, Turner D, Yang J, Neuhoff S, Polak S, Rostami-Hodjegan A, et al. Population-based mechanistic prediction of oral drug absorption. AAPS J. 2009;11(2):225\u201337.","journal-title":"AAPS J"},{"issue":"2","key":"1288_CR15","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/bdd.2072","volume":"38","author":"D Pade","year":"2017","unstructured":"Pade D, Jamei M, Rostami-Hodjegan A, Turner DB. Application of the MechPeff model to predict passive effective intestinal permeability in the different regions of the rodent small intestine and colon. Biopharm Drug Dispos. 2017;38(2):94\u2013114.","journal-title":"Biopharm Drug Dispos"},{"issue":"11","key":"1288_CR16","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1002\/jps.1132","volume":"90","author":"M Hosseini-Yeganeh","year":"2001","unstructured":"Hosseini-Yeganeh M, McLachlan AJ. Tissue distribution of terbinafine in rats. J Pharm Sci. 2001;90(11):1817\u201328.","journal-title":"J Pharm Sci"},{"issue":"4","key":"1288_CR17","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.xphs.2017.11.012","volume":"107","author":"Z Tylutki","year":"2018","unstructured":"Tylutki Z, Mendyk A, Polak S. Mechanistic physiologically based pharmacokinetic (PBPK) model of the heart accounting for inter-individual variability: development and performance verification. J Pharm Sci. 2018;107(4):1167\u201377.","journal-title":"J Pharm Sci"},{"issue":"3","key":"1288_CR18","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/clpt.1983.46","volume":"33","author":"P Schulz","year":"1983","unstructured":"Schulz P, Turner-Tamiyasu K, Smith G, Giacomini KM, Blaschke TF. Amitriptyline disposition in young and elderly normal men. Clin Pharmacol Ther. 1983;33(3):360\u20136.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1288_CR19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/BF00634149","volume":"50","author":"LF Gram","year":"1976","unstructured":"Gram LF, Andreasen PB, Overo KF, Christiansen J. Comparison of single dose kinetics of imipramine, nortriptyline and antipyrine in man. Psychopharmacology. 1976;50(1):21\u20137.","journal-title":"Psychopharmacology"},{"issue":"1","key":"1288_CR20","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/S0022-3565(24)29543-4","volume":"297","author":"K Venkatakrishnan","year":"2001","unstructured":"Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001;297(1):326\u201337.","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"1288_CR21","first-page":"740","volume":"25","author":"OV Olesen","year":"1997","unstructured":"Olesen OV, Linnet K. Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes. Drug Metab Dispos. 1997;25(6):740\u20134.","journal-title":"Drug Metab Dispos"},{"key":"1288_CR22","unstructured":"NDA 21\u2013958 Pharmacology\/Toxicology Review and Evaluation. In: Research CfDEa, editor. Food and Drug Administration; 2005. p. 19."},{"key":"1288_CR23","unstructured":"ICH. GENERAL PRINCIPLES FOR MODEL-INFORMED DRUG DEVELOPMENT M15 - Final version; 2026. Available from: https:\/\/database.ich.org\/sites\/default\/files\/ICH_M15_Step4_Final_Guideline_2026_0129.pdf\n. Accessed\u00a012 Feb 2026."},{"issue":"2","key":"1288_CR24","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1211\/0022357021778312","volume":"54","author":"MH Yeganeh","year":"2002","unstructured":"Yeganeh MH, McLachlan AJ. In-vitro distribution of terbinafine in rat and human blood. J Pharm Pharmacol. 2002;54(2):277\u201381.","journal-title":"J Pharm Pharmacol"},{"issue":"5","key":"1288_CR25","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/psp4.35","volume":"4","author":"L Zhou","year":"2015","unstructured":"Zhou L, Gan J, Yoshitsugu H, Gu X, Lutz JD, Masson E, et al. Integration of physiologically-based pharmacokinetic modeling into early clinical development: an investigation of the pharmacokinetic nonlinearity. CPT Pharmacomet Syst Pharmacol. 2015;4(5):286\u201394.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1288_CR26","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3109\/09546639009089029","volume":"1","author":"V Villars","year":"1990","unstructured":"Villars V, Jones T. Present status of the efficacy and tolerability of terbinafine (Lamisil) used systemically in the treatment of dermatomycoses of skin and nails. J Dermatolog Treat. 1990;1:33\u20138.","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"1288_CR27","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1002\/ccr3.3656","volume":"9","author":"M Ando","year":"2021","unstructured":"Ando M, Tamura R, Nakasako S, Takimoto S, Ariyoshi K, Yamaguchi M, et al. Plasma concentration of amitriptyline and metabolites after resuscitation from cardiopulmonary arrest following an overdose: a case report. Clin Case Rep. 2021;9(2):805\u201311.","journal-title":"Clin Case Rep"},{"issue":"6","key":"1288_CR28","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/sj.bjp.0707253","volume":"151","author":"PK Gillman","year":"2007","unstructured":"Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007;151(6):737\u201348.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"1288_CR29","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/sj.tpj.6500285","volume":"5","author":"M Ingelman-Sundberg","year":"2005","unstructured":"Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005;5(1):6\u201313.","journal-title":"Pharmacogenomics J"},{"key":"1288_CR30","unstructured":"Cinacalcet 021688s017lbl [Internet]. 2011. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021688s017lbl.pdf.\u00a0Accessed 25\u00a0June 2026."},{"issue":"3","key":"1288_CR31","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2165\/00003088-199426030-00004","volume":"26","author":"AC Altamura","year":"1994","unstructured":"Altamura AC, Moro AR, Percudani M. Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet. 1994;26(3):201\u201314.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1288_CR32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2165\/00003088-199733010-00002","volume":"33","author":"O Heikinheimo","year":"1997","unstructured":"Heikinheimo O. Clinical pharmacokinetics of mifepristone. Clin Pharmacokinet. 1997;33(1):7\u201317.","journal-title":"Clin Pharmacokinet"},{"key":"1288_CR33","unstructured":"Latini R, Tognoni G, Kates RE. Clinical Pharmacokinetics of Amiodarone."}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01288-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-026-01288-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01288-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:03:22Z","timestamp":1790665402000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-026-01288-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["1288"],"URL":"https:\/\/doi.org\/10.1208\/s12248-026-01288-x","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"assertion":[{"value":"3 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors are Amgen, Inc. employees and own stock or stock options. We declare that we have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"141"}}